A Systematic Review of Adjuvant Interventions for Radioiodine in Patients with Thyroid Cancer.
OBJECTIVE
The purpose of this study was to assess the effects of adjuvant interventions for radioiodine in patients with thyroid cancer.


METHODS
A systematic search was undertaken on July 9, 2014. RevMan 5 software was used to synthesize data.


RESULTS
13 randomized controlled trials were included. The pooled risk ratio of 0.99 (95% confidence interval (CI): 0.96-1.02, p = 0.58) indicated no significant difference in successful thyroid remnant ablation between recombinant human thyroid-stimulating hormone (rhTSH) and thyroid hormone withdrawal in 7 trials. The percentage of patients who had successful ablation was significantly higher in the oral-lithium group than in the control group (p = 0.017). A computerized decision aid improves informed decision-making in patients with early-stage papillary thyroid cancer (PTC) who are considering adjuvant radioiodine treatment (p < 0.001). Amifostine pretreatment did not prevent parenchymal damage to the major salivary gland function after radioiodine treatment (p = 0.2461).


CONCLUSIONS
The present systematic review suggests that rhTSH, lithium, and computerized decision aids maybe act as beneficial adjuvant interventions for radioiodine in patients with thyroid cancer; however, amifostine does not exhibit helpful effects in thyroid cancer patients treated with radioiodine.
Department of Surgery, First Affiliated Hospital of Xi'an Medical University, Xi'an, China.
Gangzhu
G
Xu
Tao
T
Wu
Liqiao
L
Ge
Wen
W
Li
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D059186:Chemoradiotherapy, Adjuvant / Q000401:mortality*; D020000:Decision Support Systems, Clinical / Q000706:statistics & numerical data*; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008297:Male; D015995:Prevalence; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D012307:Risk Factors; D015996:Survival Rate; D013964:Thyroid Neoplasms / Q000401:mortality* / Q000628:therapy*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals